Data support longer recurrence-free survival with nivolumab than with ipilimumab for stage III or IV melanoma
Early stage non–small cell lung cancer: Toward a risk-adaptive paradigm in the era of biologic precision
Redefining early stage non–small cell lung cancer: The dawn of the risk-adaptive and biologically precise era
